The development of nanoagents for the diagnosticsand targetedtherapy of cancer is one of the leading trends in modern biomedicine.Clinically significant oncomarkers that are overexpressed in certaintypes of malignant diseases, such as HER1, HER2, EpCAM, CD44, CD133,and others, are most often used as targets for drug delivery. The gene discussed is ERBB2; the disease is cancer.